ZA200703838B - Multivalent vaccines comprising recombinant viral vectors - Google Patents

Multivalent vaccines comprising recombinant viral vectors

Info

Publication number
ZA200703838B
ZA200703838B ZA2007/03838A ZA200703838A ZA200703838B ZA 200703838 B ZA200703838 B ZA 200703838B ZA 2007/03838 A ZA2007/03838 A ZA 2007/03838A ZA 200703838 A ZA200703838 A ZA 200703838A ZA 200703838 B ZA200703838 B ZA 200703838B
Authority
ZA
South Africa
Prior art keywords
viral vectors
recombinant viral
multivalent vaccines
multivalent
vaccines
Prior art date
Application number
ZA2007/03838A
Other languages
English (en)
Inventor
Menzo Jans Emco Havenga
Jerald C Sadoff
Yasir A Skeiky
Ronald Vogels
David Hone
Katarina Radosevic
Original Assignee
Crucell Holland Bv
Aeras Global Tb Vaccine Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Aeras Global Tb Vaccine Found filed Critical Crucell Holland Bv
Publication of ZA200703838B publication Critical patent/ZA200703838B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
ZA2007/03838A 2004-11-16 2007-05-11 Multivalent vaccines comprising recombinant viral vectors ZA200703838B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62825304P 2004-11-16 2004-11-16
EP04106074 2004-11-25
US65111305P 2005-02-08 2005-02-08
PCT/EP2005/055984 WO2006053871A2 (en) 2004-11-16 2005-11-15 Multivalent vaccines comprising recombinant viral vectors

Publications (1)

Publication Number Publication Date
ZA200703838B true ZA200703838B (en) 2012-07-25

Family

ID=34929936

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2007/03838A ZA200703838B (en) 2004-11-16 2007-05-11 Multivalent vaccines comprising recombinant viral vectors

Country Status (14)

Country Link
US (3) US8012467B2 (de29)
EP (1) EP1812580B1 (de29)
JP (1) JP4838259B2 (de29)
KR (1) KR101255870B1 (de29)
CN (2) CN102220357B (de29)
AU (2) AU2005305869B2 (de29)
BR (1) BRPI0518933A2 (de29)
CA (1) CA2586620C (de29)
EA (1) EA012037B1 (de29)
MX (1) MX2007005256A (de29)
NZ (2) NZ581306A (de29)
SG (2) SG159554A1 (de29)
WO (1) WO2006053871A2 (de29)
ZA (1) ZA200703838B (de29)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
BRPI0806501A2 (pt) * 2007-01-15 2014-04-22 Glaxosmithkline Biolog Sa Proteína de fusão, molécula de ácido nucleico, vetor, célula hospedeira, vacina ou composição imunogênica, e, uso da proteína de fusão.
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
EP4186978A1 (en) 2007-12-27 2023-05-31 Universität Zürich Replication-defective arenavirus vectors
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
AP2011005541A0 (en) * 2008-07-16 2011-02-28 Baylor Res Inst HIV vaccine based on targeting maximized GAG and NEF to dendritic cells.
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
EP2358757B1 (en) 2008-11-18 2018-09-12 Beth Israel Deaconess Medical Center Antiviral vaccines with improved cellular immunogenicity
TR201903223T4 (tr) * 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
CA2786835C (en) 2010-02-15 2021-08-31 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
EP2618838A1 (en) * 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
CN102154324B (zh) * 2010-12-29 2012-11-28 兰州大学 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
HUE027839T2 (en) 2012-03-12 2016-11-28 Crucell Holland Bv Recombinant adenoviruses with altered terminals
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP2015515276A (ja) 2012-04-16 2015-05-28 アエラス グローバル ティービー ワクチン ファウンデーション ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
CN103304670B (zh) * 2013-06-03 2015-09-16 中国人民解放军第三〇九医院 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用
AP2016009154A0 (en) 2013-09-19 2016-04-30 Crucell Holland Bv Improved adenovirus formulations
CN103865934B (zh) * 2014-03-26 2017-02-22 中国人民解放军成都军区疾病预防控制中心 银环毒素抗原表位基因及其在基因疫苗及抗原制备中的应用
NZ727024A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6873054B2 (ja) * 2015-06-12 2021-05-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
EA036412B1 (ru) 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CN106754758A (zh) * 2016-12-29 2017-05-31 汕头大学医学院 一种含细胞因子佐剂的重组肠道病毒表型混合系统的构建方法及其应用
CN110268061A (zh) 2017-02-09 2019-09-20 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
CN107602672B (zh) * 2017-08-30 2021-06-18 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN107365365B (zh) * 2017-08-30 2021-01-01 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
EP3700561A1 (en) 2017-10-27 2020-09-02 Statens Serum Institut A polygene influenza vaccine
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042016C (en) 1989-09-19 2004-04-06 Jean Content Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
EP0499003A1 (en) 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
AU1097795A (en) 1993-11-23 1995-06-13 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
US6599510B1 (en) 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
JPH11506320A (ja) 1995-05-23 1999-06-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物、ならびにそれらを産生および使用するための方法
EP0850305B1 (en) 1995-09-01 2006-04-26 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
TR200806259T2 (tr) 1995-09-01 2008-10-21 Corixa Corporation Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6087163A (en) 1997-02-06 2000-07-11 The Public Health Research Institute Of The City Of New York, Inc. Mycobacterium tuberculosis specific proteins and genes, mixtures of anitgens and uses thereof
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
TR199901569T2 (xx) 1996-10-11 2000-12-21 Corixa Corporation T�berk�lozun te�hisi i�in bile�ikler ve y�ntemler.
JP2001512435A (ja) 1997-01-21 2001-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物ならびにそれらの産生および使用方法
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
ES2291810T3 (es) 1997-04-02 2008-03-01 Statens Serum Institut Fragmentos de acido nucleico y fragmentos de polpeptidos derivados de m. tuberculosis.
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6436409B1 (en) 1997-07-16 2002-08-20 Institut Pasteur Polynucleotide functionally coding for the LHP protein from Mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
WO2001004151A2 (en) 1999-07-13 2001-01-18 Statens Serum Institut TUBERCULOSIS VACCINE AND DIAGNOSTICS BASED ON THE MYCOBACTERIUM TUBERCULOSIS esat-6 GENE FAMILY
EP1029053A1 (en) 1997-11-10 2000-08-23 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis
TWI243169B (en) 1998-03-02 2005-11-11 Nissan Chemical Ind Ltd Optically active epoxy compound
TR200002938T2 (tr) 1998-04-07 2001-02-21 Corixa Corporation Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı
US20020150592A1 (en) 1998-09-18 2002-10-17 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
AU766093B2 (en) 1998-10-08 2003-10-09 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
AU2594500A (en) 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
US20030027774A1 (en) 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001025401A2 (en) 1999-10-07 2001-04-12 Corixa Corporation A mycobacterium tuberculosis coding sequence for expression of heterologous proteins
JP2003510370A (ja) 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0006693D0 (en) 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
ES2374620T3 (es) 2000-06-20 2012-02-20 Corixa Corporation Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos.
AU2002318104A1 (en) * 2001-01-05 2002-11-25 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
ES2375557T3 (es) 2001-06-22 2012-03-02 The Trustees Of The University Of Pennsylvania Adenovirus recombinantes que comprenden prote�?nas de adenovirus de simios y usos de los mismos.
AU2002365366B2 (en) 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
EP1606397A1 (en) 2003-03-17 2005-12-21 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
KR100992646B1 (ko) * 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
JP2007515386A (ja) * 2003-09-18 2007-06-14 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖ感染個体の治療用免疫化
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
DK1827504T3 (da) * 2004-12-01 2011-08-29 Aeras Global Tb Vaccine Foundation Rekombinante BCG-stammer med forøget evne til at undslippe fra endosomet
CA2615983A1 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis

Also Published As

Publication number Publication date
AU2011200749B9 (en) 2012-04-05
WO2006053871A3 (en) 2006-12-21
CA2586620C (en) 2014-06-03
KR20070091620A (ko) 2007-09-11
US8012467B2 (en) 2011-09-06
EP1812580A2 (en) 2007-08-01
CA2586620A1 (en) 2006-05-26
AU2011200749B2 (en) 2012-03-01
EP1812580B1 (en) 2014-12-17
KR101255870B1 (ko) 2013-04-17
US20110281347A1 (en) 2011-11-17
US8609402B2 (en) 2013-12-17
BRPI0518933A2 (pt) 2008-12-16
EA200701084A1 (ru) 2007-10-26
WO2006053871A2 (en) 2006-05-26
AU2005305869A1 (en) 2006-05-26
EA012037B1 (ru) 2009-06-30
MX2007005256A (es) 2008-03-11
CN101090974B (zh) 2011-05-11
SG159554A1 (en) 2010-03-30
JP2008520198A (ja) 2008-06-19
SG159555A1 (en) 2010-03-30
NZ555907A (en) 2009-12-24
CN101090974A (zh) 2007-12-19
US20090123438A1 (en) 2009-05-14
NZ581306A (en) 2011-03-31
JP4838259B2 (ja) 2011-12-14
CN102220357A (zh) 2011-10-19
US8202723B2 (en) 2012-06-19
AU2005305869B2 (en) 2010-12-09
CN102220357B (zh) 2013-12-25
AU2011200749A1 (en) 2011-03-10
US20110256166A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
ZA200703838B (en) Multivalent vaccines comprising recombinant viral vectors
GB2434367B (en) Improved vaccines
EP1909829A4 (en) RECOMBINANT GRIP VACCINES
IL195683A0 (en) Recombinant viral vaccine
IL178890A0 (en) Vaccines
EP1874346A4 (en) RECOMBINANT FLAVIVIRUS VACCINES
EP1773403A4 (en) VIRAL ADJUVANZIA
ZA200802218B (en) Adenoviral vector-based malaria vaccines
SI1673460T1 (sl) Rekombinantna cepiva in njihova uporaba
GB0417494D0 (en) Vaccine
IL181733A0 (en) Vaccines comprising plasmodium antigens
SG150551A1 (en) Flavivirus vaccines
HK1200180A1 (en) Recombinant vaccine against bluetongue virus
GB0409940D0 (en) Vaccine
EP1893233A4 (en) PEPTIDES AND THERAPEUTIC VACCINES
HK1121698A1 (en) Marked bovine viral diarrhea virus vaccines
EP1718330A4 (en) COMPLEX POLYPEPTIDE AND ADJUVANT FOR ENHANCED VACCINES
GB2460969B (en) Vaccines for intranasal administration
GB0411150D0 (en) Vaccine
ZA200807552B (en) Recombinant mononegaviral virus vectors
GB0413510D0 (en) Vaccine
ZA200800566B (en) Therapeutic peptides and vaccines
GB0412407D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine